Healthcare Professional Site | Patient Site
Home About Cladribine Patient Savings Contact Prescribing Information Patient Information Leaflets
Savings are available through the Cladribine instant savings program†

Making Cladribine tablets more affordable for patients†

Apotex is pleased to offer financial assistance with cost-sharing for Cladribine tablets labeled and distributed by Apotex to eligible commercially insured patients through the Cladribine instant savings† program:

Do you have commercial health insurance?

You may be eligible for the Cladribine instant savings† program

  • If eligible, commercially insured patients may pay as little as $0† out-of-pocket cost with the Cladribine instant savings card and the program will pay up to $4,600 per calendar year.
  • Patients must deduct the savings received under this program from any reimbursement request submitted to their insurance plan, either directly by them or on their behalf.

Follow these simple steps for your Cladribine instant savings† program card:

  • Review the Terms and Conditions below.
  • Click Enroll to agree to the Terms and Conditions.
  • Print your Cladribine instant savings† program card and bring it to a participating local pharmacy.

Review the Cladribine instant savings† program Terms and Conditions here:

  • I understand this offer is not valid for patients who are uninsured or have no prescription drug coverage for Cladribine, or for patients whose prescriptions are paid for in whole or in part by either Medicaid, Medicare, TRICARE, the Federal Employee Health Benefits program, or any other Federal or State funded program.
  • I verify I have commercial health insurance and agree to the Terms and Conditions.
Enroll
†Click Enroll to agree to the Terms and Conditions and verify that you meet the eligibility requirements and get your printable Cladribine instant savings† program card.

If you have any questions regarding your eligibility or benefits, or if you wish to discontinue your participation, please call 1-833-944-5688.

Patient

  • Present the Cladribine instant savings† card with your Cladribine prescription at any participating pharmacy.
  • If eligible, commercially insured patients may pay as little as $0† out-of-pocket cost with the Cladribine instant savings card and the program will pay up to $4,600 per calendar year.
  • By using this card, the patient acknowledges meeting the eligibility requirements and complying with the Terms and Conditions.
  • For questions about eligibility or about using the card, please call toll free at 1-833-944-5688.

Pharmacist

  • For commercially insured patients presenting the Cladribine instant savings program card for whom you have dispensed Cladribine tablets (refer to this document for applicable NDCs), process a coordination of benefits claim (COB/split bill) by using the patient's prescription insurance for the PRIMARY claim.
  • Submit a SECONDARY claim to CapitalRx under BIN: 610852 and PCN: 2001.
  • For questions about processing the card, please call toll free at 1-833-944-5688.

Limitations apply

  • Offer not valid for patients who are uninsured or have no prescription drug coverage for Cladribine or those with prescription drug coverage under Medicaid, Medicare, TRICARE, the Federal Employee Health Benefit Program, or any other federal or state health care program, or if patients receive full reimbursement for prescriptions from private insurance plans or other health or pharmacy benefit programs (i.e. there is no cost-sharing obligation).

IMPORTANT SAFETY INFORMATION

CLADRIBINE may cause serious side effects, including:

  • Risk of cancer (malignancies). You should follow healthcare provider instructions about screening for cancer.
  • Risk of birth defects. CLADRIBINE may cause birth defects if used during pregnancy. Women must not be pregnant when they start treatment with CLADRIBINE or become pregnant during CLADRIBINE dosing and within 6 months after the last dose of each yearly treatment course. You should stop treatment with CLADRIBINE and contact your healthcare provider right away if you become pregnant during treatment with CLADRIBINE.

For women who are able to become pregnant:

  • Your healthcare provider should order a pregnancy test before you begin your first and second yearly treatment course of CLADRIBINE to make sure that you are not pregnant.
  • Ask your healthcare provider which contraceptive method is right for you. Women and men being treated with CLADRIBINE should use effective birth control (contraception) on the days on which they take CLADRIBINE and for at least 6 months after the last dose of each yearly treatment course.
 
 

WHAT IS CLADRIBINE?

CLADRIBINE is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, CLADRIBINE is typically used in people who have tried another type of medication for MS that they could not tolerate or that has not worked well enough.

CLADRIBINE is not recommended for use in people with clinically isolated syndrome (CIS).

It is not known if CLADRIBINE is safe and effective in children under 18 years of age and is therefore not recommended.

IMPORTANT SAFETY INFORMATION

CLADRIBINE may cause serious side effects, including:

  • Risk of cancer (malignancies). You should follow healthcare provider instructions about screening for cancer.
  • Risk of birth defects. CLADRIBINE may cause birth defects if used during pregnancy. Women must not be pregnant when they start treatment with CLADRIBINE or become pregnant during CLADRIBINE dosing and within 6 months after the last dose of each yearly treatment course. You should stop treatment with CLADRIBINE and contact your healthcare provider right away if you become pregnant during treatment with CLADRIBINE.

For women who are able to become pregnant:

  • Your healthcare provider should order a pregnancy test before you begin your first and second yearly treatment course of CLADRIBINE to make sure that you are not pregnant.
  • Ask your healthcare provider which contraceptive method is right for you. Women and men being treated with CLADRIBINE should use effective birth control (contraception) on the days on which they take CLADRIBINE and for at least 6 months after the last dose of each yearly treatment course.

Do not take CLADRIBINE if you:

  • have cancer (malignancy).
  • are pregnant, plan to become pregnant, or are a woman of childbearing age or a man able to father a child and you are not using birth control.
  • are breastfeeding.
  • are human immunodeficiency virus (HIV) positive.
  • have active infections, including tuberculosis (TB), hepatitis B or C.
  • are allergic to cladribine.

Before you take CLADRIBINE, tell your healthcare provider about all of your medical conditions, including if you:

  • think you have an infection.
  • have taken, take, or plan to take medicines that affect your immune system or blood cells, or other treatments for MS.
  • have had a recent vaccination or are scheduled to receive any vaccinations.
  • have heart failure.
  • have or have had cancer.
  • have liver or kidney problems.
  • are breastfeeding or plan to breastfeed.

How should I take CLADRIBINE?

  • CLADRIBINE is given as two yearly treatment courses, consisting of 2 treatment weeks (cycles) about a month apart.
  • Handle CLADRIBINE with dry hands and take immediately after opening the blister pack.
  • Take with water and do not chew the tablet.
  • CLADRIBINE can be taken with or without food and should be taken at least 3 hours apart from other medicines.
  • Wash your hands after handling CLADRIBINE.
  • If you miss a dose, take it as soon as you remember on the same day. If the whole day passes, take your missed dose the next day. Do not take 2 doses at the same time.

Your healthcare provider will continue to monitor your health during the 2 yearly treatment courses, and for at least another 2 years during which you do not need to take CLADRIBINE.

CLADRIBINE can cause serious side effects. Call your healthcare provider right away if you experience:

  • Low blood cell counts, which can increase your risk of infections.
  • Serious infections including TB, hepatitis B or C, and shingles.
  • Progressive multifocal leukoencephalopathy (PML).
  • Liver problems.
  • Allergic reactions.
  • Heart failure.

The most common side effects of CLADRIBINE include upper respiratory infection, headache, and low white blood cell counts.

These are not all the possible side effects of CLADRIBINE. Call your doctor for medical advice about side effects.

To report SUSPECTED ADVERSE REACTIONS, contact APOTEX at 1-800-706-5575 or the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.

Please see full Prescribing Information and Medication Guide, including serious side effects.